Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report...

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Attention deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder.
• Its pathophysiology is linked to noradrenaline and dopamine neurotransmission.
• Previous studies examined dopamine transporter (DAT) using dopamine reuptake inhibitors.

Purpose of the Study:

• To investigate the effect of atomoxetine, a selective noradrenaline reuptake inhibitor, on striatal DAT.
• To evaluate changes in DAT bioavailability after 8 weeks of atomoxetine treatment in a pilot study.

Main Methods:

• Utilized SPECT imaging to measure striatal DAT bioavailability.
• Administered atomoxetine for 8 weeks.
• Correlated DAT changes with patient genotype and clinical improvement.

Main Results:

• Eight weeks of atomoxetine treatment showed potential changes in striatal DAT bioavailability.
• No correlation was found between DAT changes and patient genotype.
• No correlation was observed between DAT changes and clinical improvement.

Conclusions:

• Atomoxetine may influence striatal DAT bioavailability.
• The observed changes in DAT are not associated with genetic factors or symptom reduction in ADHD.
• Further research is needed to understand the clinical implications of atomoxetine's effect on DAT.